Early-stage venture sourcing has become a timing problem.
By the time a company appears with a clean profile, round history, investor list, and market description in a private-market database, the first sourcing window has often passed. The company has already formed, raised attention, entered investor workflows, or started conversations with funds that found the signal earlier.
This matters most in science-driven markets.
In life sciences, many venture targets begin inside universities, hospitals, research institutes, translational labs, grant programmes, technology transfer offices, and founder networks long before they look like conventional startups. The earliest signal is often a publication, patent, grant, conference abstract, investigator profile, lab spinout notice, clinical translation effort, or licensing pathway.
The opportunity is real. AUTM describes technology transfer data as covering licensing, startup, patenting, and commercialization activity from more than 230 research institutions across the United States and Canada. [1] In Europe, the 2025 European Spinouts Report highlighted the growing importance of deep-tech and life-science spinouts, with more than 7,300 companies and a combined value of $398 billion. [2] The Max Planck Society reported that deep-tech and life-science startups emerging from European research institutions have grown from around 100 per year between 2000 and 2010 to more than 500 annually since 2015. [3]
This creates a sourcing gap.
PitchBook and Dealroom are essential parts of the venture workflow
PitchBook provides private-market data across companies, investors, deals, funds, valuations, executives, and professionals. [4] Dealroom tracks startups, venture capital activity, funding rounds, valuations, business models, and emerging trends. [5]
Those platforms become strongest once a company is visible as a company.
MNTR focuses on the earlier layer: the research, institutional, technical, and commercial signals that indicate where a company is likely to emerge.
An Early-Stage Target Identification World starts with a defined investment focus
This can be a therapeutic area, modality, platform technology, university cluster, research institution, founder profile, disease field, or translational pathway. MNTR monitors the sources around that focus and connects signals into an investable view.
For a life-science investor, this means tracking where scientific momentum, founder formation, IP activity, translational funding, and institutional support begin to converge.
A paper gains relevance when the same lab receives translational funding. A patent gains relevance when it connects to a known principal investigator, disease area, or platform. A grant gains relevance when it supports work that moves from discovery toward application. A tech-transfer notice gains relevance when it points to a forming company, licensing route, or repeat founder pattern.
The value lies in turning scattered research signals into a sourcing pipeline
World gives the investor a current view of the field in scope: the institutions, labs, investigators, technologies, companies, and funding signals connected to the investment theme. Thesis tracks the assumptions behind the sourcing strategy, such as which modality is gaining traction, which research cluster is producing spinouts, or which translational pathway is becoming investable. Paths connect scientific signals to possible company formation, commercial relevance, and deal ownership. Search gives cited answers across the monitored material. Intel turns relevant changes into briefings for the investment team.
This changes the sourcing workflow
A fund no longer starts only with companies already named in a database. It starts with the scientific and institutional activity that creates those companies. The team sees which labs are publishing, which investigators are receiving funding, which patents connect to which fields, which institutions are spinning out companies, and which signals are strengthening around a potential opportunity.
That operating view is especially valuable in life sciences because the company often arrives late in the signal chain. The science, IP, team formation, and institutional context appear first.
MNTR gives investors a way to monitor that pre-company layer.
The first world can be narrow
One disease area, one modality, one university cluster, one therapeutic platform, or one translational funding stream. MNTR monitors the relevant sources and helps the team move from signal to target: what changed, why it matters, which opportunity is forming, and who owns the next step.
Early-stage sourcing rewards investors who see the pattern before it becomes a profile
Sources
- [1] AUTM, “Technology Transfer Licensing Survey.” https://autm.net/surveys-and-tools/surveys/licensing-survey
- [2] Cambridge Innovation Capital, “European deeptech and life sciences spinouts worth $398bn.” https://www.cic.vc/european-deeptech-and-life-sciences-spinouts-worth-398bn/
- [3] Max Planck Society, “European Spinouts Report 2025: Max Planck leads the way in Germany.” https://www.mpg.de/25797163/european-spinouts-report-2025-max-planck-leads-the-way-in-germany
- [4] PitchBook, “Private & Public Company Data.” https://pitchbook.com/platform-data/companies
- [5] Dealroom, “About Dealroom.” https://dealroom.co/about/
